Lung Cancer Diagnostics Market to 2027 - Global Analysis and Forecasts by Test (Sputum Cytology, Biopsy, Imaging, Molecular Test, and Other Tests), Technology (Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), and Other Technologies), and Geography
Report Code: TIPRE00003018 No. of Pages: 150 Category: Medical Device Status: Upcoming
Lung cancer begins in the lungs, and is basically of two types, known as, small cell lung cancer and non-small cell lung cancer. Lung cancer is largely seen in individuals with smoking habits. It is also considered to be the second leading cause of deaths in the United States. By conducting diagnostic tests within time, it is possible to effectively treat the cancer and also accordingly control the spreading of tumor.
Increasing prevalence of lung cancer as well as increase in smoking habits among youth is expected to fuel the growth of the lung cancer diagnosis market during the forecast period. Moreover, the introduction of new and better products by manufacturers is anticipated to offer growth opportunities to the companies in the market.
The "Global Lung Cancer Diagnosis Market Analysis to 2027" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by test, technology and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading lung cancer diagnosis market players and offers key trends and opportunities in the market.
The global lung cancer diagnosis market is segmented on the basis of test and technology. Based on test, the market is segmented as, sputum cytology, biopsy, imaging, molecular test, and other tests. On the basis of technology, the lung cancer diagnosis market is classified as, fluorescent in situ hybridization (FISH), immunohistochemical (IHC), and other technologies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global lung cancer diagnosis market based on test and technology. It also provides market size and forecast till 2027 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lung cancer diagnosis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the lung cancer diagnosis market in the coming years, owing to rising prevalence of lung cancer cases in the region during the recent years. Asia Pacific is expected to witness significant growth in the market during the forecast period, due to changing lifestyle trends and increase in smoking among the young population.
The report analyzes factors affecting lung cancer diagnosis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lung cancer diagnosis market in these regions.
The report also includes the profiles of key lung cancer diagnosis companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the lung cancer diagnosis market include, Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Koninklijke Philips N.V., Oncimmune Holdings Plc, OncoCyte Corporation, QIAGEN, Quest Diagnostics, and Siemens Healthcare GmbH among others.
Increasing prevalence of lung cancer as well as increase in smoking habits among youth is expected to fuel the growth of the lung cancer diagnosis market during the forecast period. Moreover, the introduction of new and better products by manufacturers is anticipated to offer growth opportunities to the companies in the market.
The "Global Lung Cancer Diagnosis Market Analysis to 2027" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by test, technology and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading lung cancer diagnosis market players and offers key trends and opportunities in the market.
The global lung cancer diagnosis market is segmented on the basis of test and technology. Based on test, the market is segmented as, sputum cytology, biopsy, imaging, molecular test, and other tests. On the basis of technology, the lung cancer diagnosis market is classified as, fluorescent in situ hybridization (FISH), immunohistochemical (IHC), and other technologies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global lung cancer diagnosis market based on test and technology. It also provides market size and forecast till 2027 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lung cancer diagnosis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the lung cancer diagnosis market in the coming years, owing to rising prevalence of lung cancer cases in the region during the recent years. Asia Pacific is expected to witness significant growth in the market during the forecast period, due to changing lifestyle trends and increase in smoking among the young population.
The report analyzes factors affecting lung cancer diagnosis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lung cancer diagnosis market in these regions.
The report also includes the profiles of key lung cancer diagnosis companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the lung cancer diagnosis market include, Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Koninklijke Philips N.V., Oncimmune Holdings Plc, OncoCyte Corporation, QIAGEN, Quest Diagnostics, and Siemens Healthcare GmbH among others.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1. Breast Cancer Diagnostics Market- By Test
1.3.2. Breast Cancer Diagnostics Market- By Technology
1.3.3. Breast Cancer Diagnostics Market- By Region
1.3.3.1. By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BREAST CANCER DIAGNOSTICS MARKET LANDSCAPE
4.1. MARKET OVERVIEW
4.2. PEST ANALYSIS
4.2.1. North America - PEST Analysis
4.2.2. Europe - PEST Analysis
4.2.3. Asia Pacific - PEST Analysis
4.2.4. Middle East & Africa - PEST Analysis
4.2.5. South and Central America - PEST Analysis
5. BREAST CANCER DIAGNOSTICS MARKET- KEY INDUSTRY DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BREAST CANCER DIAGNOSTICS MARKET- GLOBAL ANALYSIS
6.1. BREAST CANCER DIAGNOSTICS MARKET - GLOBAL MARKET OVERVIEW
6.2. BREAST CANCER DIAGNOSTICS MARKET - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/ MARKET SHARE OF KEY PLAYERS
7. BREAST CANCER DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2027 - TEST
7.1. OVERVIEW
7.2. TEST MARKET FORECASTS AND ANALYSIS
7.3. SPUTUM CYTOLOGY MARKET
7.3.1. Overview
7.3.2. Sputum Cytology Market Forecast and Analysis (US$ Mn)
7.4. BIOPSY MARKET
7.4.1. Overview
7.4.2. Biopsy Market Forecast and Analysis (US$ Mn)
7.5. IMAGING MARKET
7.5.1. Overview
7.5.2. Imaging Market Forecast and Analysis (US$ Mn)
7.6. MOLECULAR TEST MARKET
7.6.1. Overview
7.6.2. Molecular Test Market Forecast and Analysis (US$ Mn)
7.7. OTHER TESTS MARKET
7.7.1. Overview
7.7.2. Other Tests Market Forecast and Analysis (US$ Mn)
8. BREAST CANCER DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2027 - TECHNOLOGY
8.1. OVERVIEW
8.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
8.3. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
8.3.1. Overview
8.3.2. Fluorescent In Situ Hybridization (FISH) Market Forecast and Analysis (US$ Mn)
8.4. IMMUNOHISTOCHEMICAL (IHC) MARKET
8.4.1. Overview
8.4.2. Immunohistochemical (IHC) Market Forecast and Analysis (US$ Mn)
8.5. OTHER TECHNOLOGIES MARKET
8.5.1. Overview
8.5.2. Other Technologies Market Forecast and Analysis (US$ Mn)
9. BREAST CANCER DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET
9.1.1. North America Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.1.2. North America Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.3. North America Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.1.4. North America Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.1.5. US Market Overview
9.1.5.1. US Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.5.2. US Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.1.6. Canada Market Overview
9.1.6.1. Canada Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.6.2. Canada Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.1.7. Mexico Market Overview
9.1.7.1. Mexico Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.7.2. Mexico Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2. EUROPE BREAST CANCER DIAGNOSTICS MARKET
9.2.1. Europe Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.2.2. Europe Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.3. Europe Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2.4. Europe Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.2.5. UK Market Overview
9.2.5.1. UK Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.5.2. UK Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2.6. Germany Market Overview
9.2.6.1. Germany Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.6.2. Germany Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2.7. France Market Overview
9.2.7.1. France Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.7.2. France Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3. ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET
9.3.1. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.3.2. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.3. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3.4. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.3.5. Japan Market Overview
9.3.5.1. Japan Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.5.2. Japan Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3.6. India Market Overview
9.3.6.1. India Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.6.2. India Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3.7. China Market Overview
9.3.7.1. China Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.7.2. China Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4. MIDDLE EAST & AFRICA (MEA) BREAST CANCER DIAGNOSTICS MARKET
9.4.1. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.4.2. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.3. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4.4. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.4.5. South Africa Market Overview
9.4.5.1. South Africa Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.5.2. South Africa Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4.6. Saudi Arabia Market Overview
9.4.6.1. Saudi Arabia Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.6.2. Saudi Arabia Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4.7. UAE Market Overview
9.4.7.1. UAE Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.7.2. UAE Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.5. SOUTH AND CENTRAL AMERICA BREAST CANCER DIAGNOSTICS MARKET
9.5.1. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.5.2. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.5.3. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.5.4. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.5.5. Brazil Market Overview
9.5.5.1. Brazil Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.5.5.2. Brazil Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
10. INDUSTRY LANDSCAPE
10.1. ORGANIC GROWTH STRATEGIES
10.1.1. New Product Launches
10.1.2. Marketing & Promotional Activities
10.2. INORGANIC GROWTH STRATEGIES
10.2.1. Partnerships, Collaborations, and Joint Ventures
10.2.2. Mergers & Acquisitions
11. BREAST CANCER DIAGNOSTICS MARKET, KEY COMPANY PROFILES
11.1. ABBOTT
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Financial Overview
11.1.4. Product/Service Portfolio
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. AGILENT TECHNOLOGIES
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Financial Overview
11.2.4. Product/Service Portfolio
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. F. HOFFMANN-LA ROCHE LTD
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Financial Overview
11.3.4. Product/Service Portfolio
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GENERAL ELECTRIC COMPANY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Financial Overview
11.4.4. Product/Service Portfolio
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. KONINKLIJKE PHILIPS N.V.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Financial Overview
11.5.4. Product/Service Portfolio
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ONCIMMUNE HOLDINGS PLC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Financial Overview
11.6.4. Product/Service Portfolio
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ONCOCYTE CORPORATION
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Financial Overview
11.7.4. Product/Service Portfolio
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. QIAGEN
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Financial Overview
11.8.4. Product/Service Portfolio
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. QUEST DIAGNOSTICS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Financial Overview
11.9.4. Product/Service Portfolio
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SIEMENS HEALTHCARE GMBH
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Financial Overview
11.10.4. Product/Service Portfolio
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1. Breast Cancer Diagnostics Market- By Test
1.3.2. Breast Cancer Diagnostics Market- By Technology
1.3.3. Breast Cancer Diagnostics Market- By Region
1.3.3.1. By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BREAST CANCER DIAGNOSTICS MARKET LANDSCAPE
4.1. MARKET OVERVIEW
4.2. PEST ANALYSIS
4.2.1. North America - PEST Analysis
4.2.2. Europe - PEST Analysis
4.2.3. Asia Pacific - PEST Analysis
4.2.4. Middle East & Africa - PEST Analysis
4.2.5. South and Central America - PEST Analysis
5. BREAST CANCER DIAGNOSTICS MARKET- KEY INDUSTRY DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BREAST CANCER DIAGNOSTICS MARKET- GLOBAL ANALYSIS
6.1. BREAST CANCER DIAGNOSTICS MARKET - GLOBAL MARKET OVERVIEW
6.2. BREAST CANCER DIAGNOSTICS MARKET - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/ MARKET SHARE OF KEY PLAYERS
7. BREAST CANCER DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2027 - TEST
7.1. OVERVIEW
7.2. TEST MARKET FORECASTS AND ANALYSIS
7.3. SPUTUM CYTOLOGY MARKET
7.3.1. Overview
7.3.2. Sputum Cytology Market Forecast and Analysis (US$ Mn)
7.4. BIOPSY MARKET
7.4.1. Overview
7.4.2. Biopsy Market Forecast and Analysis (US$ Mn)
7.5. IMAGING MARKET
7.5.1. Overview
7.5.2. Imaging Market Forecast and Analysis (US$ Mn)
7.6. MOLECULAR TEST MARKET
7.6.1. Overview
7.6.2. Molecular Test Market Forecast and Analysis (US$ Mn)
7.7. OTHER TESTS MARKET
7.7.1. Overview
7.7.2. Other Tests Market Forecast and Analysis (US$ Mn)
8. BREAST CANCER DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2027 - TECHNOLOGY
8.1. OVERVIEW
8.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
8.3. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
8.3.1. Overview
8.3.2. Fluorescent In Situ Hybridization (FISH) Market Forecast and Analysis (US$ Mn)
8.4. IMMUNOHISTOCHEMICAL (IHC) MARKET
8.4.1. Overview
8.4.2. Immunohistochemical (IHC) Market Forecast and Analysis (US$ Mn)
8.5. OTHER TECHNOLOGIES MARKET
8.5.1. Overview
8.5.2. Other Technologies Market Forecast and Analysis (US$ Mn)
9. BREAST CANCER DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET
9.1.1. North America Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.1.2. North America Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.3. North America Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.1.4. North America Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.1.5. US Market Overview
9.1.5.1. US Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.5.2. US Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.1.6. Canada Market Overview
9.1.6.1. Canada Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.6.2. Canada Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.1.7. Mexico Market Overview
9.1.7.1. Mexico Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.1.7.2. Mexico Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2. EUROPE BREAST CANCER DIAGNOSTICS MARKET
9.2.1. Europe Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.2.2. Europe Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.3. Europe Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2.4. Europe Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.2.5. UK Market Overview
9.2.5.1. UK Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.5.2. UK Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2.6. Germany Market Overview
9.2.6.1. Germany Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.6.2. Germany Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.2.7. France Market Overview
9.2.7.1. France Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.2.7.2. France Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3. ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET
9.3.1. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.3.2. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.3. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3.4. Asia Pacific Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.3.5. Japan Market Overview
9.3.5.1. Japan Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.5.2. Japan Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3.6. India Market Overview
9.3.6.1. India Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.6.2. India Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.3.7. China Market Overview
9.3.7.1. China Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.3.7.2. China Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4. MIDDLE EAST & AFRICA (MEA) BREAST CANCER DIAGNOSTICS MARKET
9.4.1. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.4.2. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.3. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4.4. Middle East & Africa (MEA) Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.4.5. South Africa Market Overview
9.4.5.1. South Africa Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.5.2. South Africa Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4.6. Saudi Arabia Market Overview
9.4.6.1. Saudi Arabia Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.6.2. Saudi Arabia Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.4.7. UAE Market Overview
9.4.7.1. UAE Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.4.7.2. UAE Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.5. SOUTH AND CENTRAL AMERICA BREAST CANCER DIAGNOSTICS MARKET
9.5.1. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis (US$ Mn)
9.5.2. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.5.3. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
9.5.4. South and Central America Breast Cancer Diagnostics Market Forecasts and Analysis - By Country
9.5.5. Brazil Market Overview
9.5.5.1. Brazil Breast Cancer Diagnostics Market Forecasts and Analysis - By Test (US$ Mn)
9.5.5.2. Brazil Breast Cancer Diagnostics Market Forecasts and Analysis - By Technology (US$ Mn)
10. INDUSTRY LANDSCAPE
10.1. ORGANIC GROWTH STRATEGIES
10.1.1. New Product Launches
10.1.2. Marketing & Promotional Activities
10.2. INORGANIC GROWTH STRATEGIES
10.2.1. Partnerships, Collaborations, and Joint Ventures
10.2.2. Mergers & Acquisitions
11. BREAST CANCER DIAGNOSTICS MARKET, KEY COMPANY PROFILES
11.1. ABBOTT
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Financial Overview
11.1.4. Product/Service Portfolio
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. AGILENT TECHNOLOGIES
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Financial Overview
11.2.4. Product/Service Portfolio
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. F. HOFFMANN-LA ROCHE LTD
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Financial Overview
11.3.4. Product/Service Portfolio
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GENERAL ELECTRIC COMPANY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Financial Overview
11.4.4. Product/Service Portfolio
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. KONINKLIJKE PHILIPS N.V.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Financial Overview
11.5.4. Product/Service Portfolio
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ONCIMMUNE HOLDINGS PLC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Financial Overview
11.6.4. Product/Service Portfolio
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ONCOCYTE CORPORATION
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Financial Overview
11.7.4. Product/Service Portfolio
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. QIAGEN
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Financial Overview
11.8.4. Product/Service Portfolio
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. QUEST DIAGNOSTICS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Financial Overview
11.9.4. Product/Service Portfolio
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SIEMENS HEALTHCARE GMBH
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Financial Overview
11.10.4. Product/Service Portfolio
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Abbott
2. Agilent Technologies
3. F. Hoffmann-La Roche Ltd
4. GENERAL ELECTRIC COMPANY
5. Koninklijke Philips N.V.
6. Oncimmune Holdings Plc
7. OncoCyte Corporation
8. QIAGEN
9. Quest Diagnostics
10. Siemens Healthcare GmbH
1. Abbott
2. Agilent Technologies
3. F. Hoffmann-La Roche Ltd
4. GENERAL ELECTRIC COMPANY
5. Koninklijke Philips N.V.
6. Oncimmune Holdings Plc
7. OncoCyte Corporation
8. QIAGEN
9. Quest Diagnostics
10. Siemens Healthcare GmbH